preclinical_heavy
Preclinical evidence exceeds central human evidence. Interpret translational relevance cautiously.
supportedtophigh inflation risk
Lipopolysaccharide biosynthesis
crohn's disease
Lipopolysaccharide biosynthesis has meaningful literature visibility in crohn's disease, but the current evidence mix suggests a substantial risk of overclaiming.
Lipopolysaccharide biosynthesis shows a moderate evidence base in crohn's disease, with multiple central papers and additional supporting literature.
lipopolysaccharide_biosynthesis
Credibility score
54
Human translation
1/5
Reproducibility
4/5
Novelty
2/5
Actionability
3/5
Credibility 54Human translation 1/5Reproducibility 4/5Novelty 2/5Actionability 3/5
Why this scores the way it does
- moderate central evidence base
- dense review literature
- substantial preclinical support
Main caveats
- preclinical evidence outweighs human evidence
Internal review flags
1 flagsPrimary central evidence
11 papersA frameshift mutation in NOD2 associated with susceptibility to Crohn's disease.
2001Nature
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Characteristics of mucosa-associated gut microbiota during treatment in Crohn's disease.
2019World journal of gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Differentially Abundant Bacterial Taxa Associated with Prognostic Variables of Crohn's Disease: Results from the IMPACT Study.
2020Journal of clinical medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Microbial Signature in Adipose Tissue of Crohn's Disease Patients.
2020Journal of clinical medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Translocation of Viable Gut Microbiota to Mesenteric Adipose Drives Formation of Creeping Fat in Humans.
2020Cell
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Alterations of Gut Microbiota in Patients With Intestinal Tuberculosis That Different From Crohn's Disease.
2021Frontiers in bioengineering and biotechnology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Identification of a choroid plexus vascular barrier closing during intestinal inflammation.
2021Science (New York, N.Y.)
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gallic acid attenuates LPS-induced inflammation in Caco-2 cells by suppressing the activation of the NF-κB/MAPK signaling pathway.
2024Acta biochimica et biophysica Sinica
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Establishment of a 3D multi-layered in vitro model of inflammatory bowel disease.
2025Journal of controlled release : official journal of the Controlled Release Society
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Biosilicification-mimicking chiral nanostructures for targeted treatment of inflammatory bowel disease.
2025Nature communications
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Low butyrate concentrations exert anti-inflammatory and high concentrations exert pro-inflammatory effects on macrophages.
2025The Journal of nutritional biochemistry
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Supporting primary evidence
1 papersDeep Sequencing of Crohn's Disease Lamina Propria Phagocytes Identifies Pathobionts and Correlates With Pro-Inflammatory Gene Expression.
2025Inflammatory bowel diseases
Human primary paper with plausible association relevance to the disease context.
Preclinical supporting evidence
33 papersThe microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition.
2014Proceedings of the National Academy of Sciences of the United States of America
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Sodium Butyrate Inhibits Inflammation and Maintains Epithelium Barrier Integrity in a TNBS-induced Inflammatory Bowel Disease Mice Model.
2018EBioMedicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
YAP Aggravates Inflammatory Bowel Disease by Regulating M1/M2 Macrophage Polarization and Gut Microbial Homeostasis.
2019Cell reports
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Lipopolysaccharides modulate intestinal epithelial permeability and inflammation in a species-specific manner.
2020Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Paeoniflorin Prevents Intestinal Barrier Disruption and Inhibits Lipopolysaccharide (LPS)-Induced Inflammation in Caco-2 Cell Monolayers.
2019Inflammation
Disease-relevant preclinical or model-based paper useful as supporting evidence.
NEK7 interacts with NLRP3 to modulate the pyroptosis in inflammatory bowel disease via NF-κB signaling.
2019Cell death & disease
Disease-relevant preclinical or model-based paper useful as supporting evidence.
PIK3R3 regulates ZO-1 expression through the NF-kB pathway in inflammatory bowel disease.
2020International immunopharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Synbindin restrains proinflammatory macrophage activation against microbiota and mucosal inflammation during colitis.
2021Gut
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Human autoinflammatory disease reveals ELF4 as a transcriptional regulator of inflammation.
2021Nature immunology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
DSS-induced inflammation in the colon drives a proinflammatory signature in the brain that is ameliorated by prophylactic treatment with the S100A9 inhibitor paquinimod.
2021Journal of neuroinflammation
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Ganluyin ameliorates DSS-induced ulcerative colitis by inhibiting the enteric-origin LPS/TLR4/NF-κB pathway.
2022Journal of ethnopharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Dioscin ameliorates inflammatory bowel disease by up-regulating miR-125a-5p to regulate macrophage polarization.
2022Journal of clinical laboratory analysis
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Enterococcus faecium and Pediococcus acidilactici deteriorate Enterobacteriaceae-induced depression and colitis in mice.
2022Scientific reports
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Turmeric-derived nanovesicles as novel nanobiologics for targeted therapy of ulcerative colitis.
2022Theranostics
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Roseburia intestinalis stimulates TLR5-dependent intestinal immunity against Crohn's disease.
2022EBioMedicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Inflammation in the peripheral blood system of Crohn's Disease.
2023Clinical and experimental medicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Disulfiram with Cu2+ alleviates dextran sulfate sodium-induced ulcerative colitis in mice.
2023Theranostics
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Effect of Extracelluar Vesicles Derived from Akkermansia muciniphila on Intestinal Barrier in Colitis Mice.
2023Nutrients
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Repurposing TAK875 as a novel STAT3 inhibitor for treating inflammatory bowel disease.
2024Biochemical pharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Elevated WTAP promotes hyperinflammation by increasing m6A modification in inflammatory disease models.
2024The Journal of clinical investigation
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Galactooligosaccharides and Limosilactobacillus reuteri synergistically alleviate gut inflammation and barrier dysfunction by enriching Bacteroides acidifaciens for pentadecanoic acid biosynthesis.
2024Nature communications
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Effects of water-insoluble wheat bran-fraction powder on disease activity and caecal microbiota in dextran sodium sulphate-induced inflammatory bowel disease mouse model.
2024Molecular biology reports
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Extracellular Vesicles Derived from Lipopolysaccharide-Pretreated Periodontal Ligament Stem Cells Ameliorate Inflammatory Responses in Experimental Colitis via the PI3K/AKT Signaling Pathway.
2024International journal of nanomedicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
AhR-Induced Anti-Inflammatory Effects on a Caco-2/THP-1 Co-Culture Model of Intestinal Inflammation Are Mediated by PPARγ.
2024International journal of molecular sciences
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Therapeutic potential of tryptophan metabolite indoleacrylic acid in inflammatory bowel disease: From cellular mechanisms to zebrafish stress-like behavior.
2025International immunopharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Encapsulated hesperetin modulates inflammatory responses in an in vitro intestinal immune co-culture model.
2025Food research international (Ottawa, Ont.)
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Bacterial membrane vesicles restore gut anaerobiosis.
2025NPJ biofilms and microbiomes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Therapeutic effects of D-cycloserine in mouse models of IBD and CAC: Targeting NLRP3 inflammasome and intestinal barrier integrity.
2025International immunopharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Intestinal inflammation and microbiota modulation impact cochlear function: emerging insights in gut-ear axis.
2025Cell communication and signaling : CCS
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Magnoflorine alleviates colitis-induced anxiety-like behaviors by regulating gut microbiota and microglia-mediated neuroinflammation.
2025Microbiome
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Veillonella intestinal colonization promotes C. difficile infection in Crohn's disease.
2025Cell host & microbe
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Faecalibacterium prausnitzii Induces an Anti-inflammatory Response and a Metabolic Reprogramming in Human Monocytes.
2026Gastroenterology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
The Crohn's disease-related RNF123 prevents NLRP3 inflammasome assembly by catalyzing unanchored K63-linked ubiquitination on NEK7.
2026Proceedings of the National Academy of Sciences of the United States of America
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Review supporting evidence
14 papersThe Roles of Cathelicidin LL-37 in Inflammatory Bowel Disease.
2016Inflammatory bowel diseases
Relevant review or meta-analysis for the signal-disease area.
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
2020Autophagy
Relevant review or meta-analysis for the signal-disease area.
Anti-Inflammatory and Immunomodulatory Effects of Probiotics in Gut Inflammation: A Door to the Body.
2021Frontiers in immunology
Relevant review or meta-analysis for the signal-disease area.
Role of the IL23/IL17 Pathway in Crohn's Disease.
2021Frontiers in immunology
Relevant review or meta-analysis for the signal-disease area.
Interaction between Lipopolysaccharide and Gut Microbiota in Inflammatory Bowel Diseases.
2021International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.
The influence of the gut microbiota on the bioavailability of oral drugs.
2021Acta pharmaceutica Sinica. B
Relevant review or meta-analysis for the signal-disease area.
Extracellular vesicles-mediated interaction within intestinal microenvironment in inflammatory bowel disease.
2022Journal of advanced research
Relevant review or meta-analysis for the signal-disease area.
The double-edged sword of probiotic supplementation on gut microbiota structure in Helicobacter pylori management.
2022Gut microbes
Relevant review or meta-analysis for the signal-disease area.
Intestinal phages interact with bacteria and are involved in human diseases.
2022Gut microbes
Relevant review or meta-analysis for the signal-disease area.
Gut Barrier Dysfunction and Bacterial Lipopolysaccharides in Colorectal Cancer.
2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
Relevant review or meta-analysis for the signal-disease area.
Association between Gut Dysbiosis and the Occurrence of SIBO, LIBO, SIFO and IMO.
2023Microorganisms
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review.
2024Internal and emergency medicine
Relevant review or meta-analysis for the signal-disease area.
Microbiota and Lipotoxicity.
2024Advances in experimental medicine and biology
Relevant review or meta-analysis for the signal-disease area.
Gut dysbiosis mediates the association between antibiotic exposure and chronic disease.
2024Frontiers in medicine
Relevant review or meta-analysis for the signal-disease area.